AU2024352372A1 — An oral liquid formulation of metoprolol
Assigned to Liqmeds Worldwide Ltd · Expires 2026-04-09 · 0y expired
What this patent protects
The present invention is related to an oral liquid formulation of metoprolol. The present invention is also related to an oral liquid formulation of metoprolol which comprises metoprolol or pharmaceutically acceptable salts thereof; one or more buffering agent; at least one vehic…
USPTO Abstract
The present invention is related to an oral liquid formulation of metoprolol. The present invention is also related to an oral liquid formulation of metoprolol which comprises metoprolol or pharmaceutically acceptable salts thereof; one or more buffering agent; at least one vehicle, and one or more pharmaceutically acceptable excipients. The present invention is also related to the process of preparation of an oral liquid formulation of metoprolol.
Drugs covered by this patent
- Robaxin (METHOCARBAMOL) · Hikma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.